Advanced periductal fibrosis from infection with the carcinogenic human liver fluke Opisthorchis viverrini correlates with elevated levels of interleukin-6

Hepatology

Volumn 50, Issue 4, 2009, Pages 1273-1281

  Sripa, Banchob ^a   Mairiang, Eimorn ^a   Thinkhamrop, Bandit ^a   Laha, Thewarach ^a   Kaewkes, Sasithorn ^a   Sithithaworn, Paiboon ^a   Tessana, Smarn ^a   Loukas, Alex ^b   Brindley, Paul J ^c   Bethony, Jeffrey M ^c  

^a KHON KAEN UNIVERSITY   (Thailand)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; BIOLOGICAL MARKER;

AGE DISTRIBUTION; ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT FIBROSIS; CASE CONTROL STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; FEMALE; GALLBLADDER CONTRACTION; HEPATOBILIARY DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPISTHORCHIASIS; OPISTHORCHIS VIVERRINI; PATHOGENESIS; PERIDUCTAL FIBROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RISK ASSESSMENT; SEX DIFFERENCE; ADULT; ANIMAL; BLOOD; GALLBLADDER; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; OPISTHORCHIS; PARASITOLOGY; PATHOGENICITY; PATHOLOGY; PATHOPHYSIOLOGY; RISK FACTOR;

ADULT; ANIMALS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; GALLBLADDER; HUMANS; INTERLEUKIN-6; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; OPISTHORCHIASIS; OPISTHORCHIS; RISK FACTORS;

EID: 70350041520     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.23134     Document Type: Article

References (47)

1. Keiser J, Utzinger J. Emerging foodborne trematodiasis. Emerg Infect Dis 2005;11:1507-1514.
2. Hotez PJ, Brindley PJ, Bethony JM, King CH, Pearce EJ, Jacobson J. Helminth infections: the great neglected tropical diseases. J Clin Invest 2008;118:1311-1321.
3. Sripa B, Kwaekes S, Sithithaworn P, Mairiang E, Laha T, Smout M, et al. Liver fluke induces cholangiocarcinoma. PLoS Med 2007;e201.
4. Sripa B. Pathobiology of opisthorchiasis: an update. Acta Trop 2003;88:209-220.
5. IARC. Schistosomes, liver flukes and Helicobacter pylori. IARC working group on the evaluation of carcinogenic risks to humans. IARC Monogr Eval Carcinog Risks Hum 1994;61:1-241.
6. Parkin DM. The global health burden of infection-associated cancers in the year. Int J Cancer 2002;118:3030-3044.
7. King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helminthic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet 2005;365:1561-1569.
8. King CH, Dangerfield-Cha M. The unacknowledged impact of chronic schistosomiasis. Chronic Ill 2008;4:65-79.
9. Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 2007;117:524-529.
10. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199-210.
11. Sithithaworn P, Haswell-Elkins M. Epidemiology of Opisthorchis viverrini. Acta Trop 2003;88:187-194.
12. Mairiang E, Chaiyakum J, Chamadol N, Laopaiboon V, Srinakarin J, Kunpitaya J, et al. Ultrasound screening for Opisthorchis viverrini-associated cholangiocarcinomas: experience in an endemic area. Asian Pac J Cancer Prev 2006;7:431-433.
13. Lim JH, Mairiang E, Ahn GH. Biliary parasitic diseases including clonorchiasis, opisthorchiasis and fascioliasis. Abdom Imaging 2008;33:157-165.
14. Mairiang E, Mairiang P Clinical manifestation of opisthorchiasis and treatment. Acta Trop 2003;88:221-227.
15. Elkins DB, Mairiang E, Sithithaworn P, Mairiang P, Chaiyakum J, Chamadol N, et al. Cross-sectional patterns of hepatobiliary abnormalities and possible precursor conditions of cholangiocarcinoma associated with Opisthorchis viverrini infection in humans. Am J Trop Med Hyg 1996;55:295-301.
16. Satarug S, Haswell-Elkins MR, Sithithaworn P, Bartsch H, Ohshima H, Tsuda M, et al. Relationships between the synthesis of N-nitrosodimethylamine and immune responses to chronic infection with the carcinogenic parasite, Opisthorchis viverrini, in men. Carcinogenesis 1998;19:485-491.
17. Naugler WE, Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 2008;14:109-119.
18. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2006;2:619-626.
19. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 2006;124:823-835.
20. Khoruts A, Stahnke L, McClain CJ, Logan G, Allen JI. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. HEPATOLOGY 1991;13:267-276.
21. Kakumu S, Shinagawa T, Ishikawa T, Yoshioka K, Wakita T, Ito Y, et al. Serum interleukin 6 levels in patients with chronic hepatitis B. Am J Gastroenterol 1991;86:1804-1808.
22. Mauad TH, van Nieuwkerk CM, Dingemans KP, Smit JJ, Schinkel AH, Notenboom RG, et al. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol 1994;145:1237-1245.
23. Malaguarnera M, Trovato BA, Laurino A, Di Fazio I, Romeo MA, Motta M. Interleukin-6 in hepatitis C cirrhosis. Panminerva Med 1996;38:207-210.
24. Malaguarnera M, Di Fazio I, Laurino A, Ferlito L, Romano M, Trovato BA. Serum Interleukin 6 concentrations in chronic hepatitis C patients before and after interferon-alpha treatment. Int J Clin Pharmacol Ther 1997;35:385-388.
25. Malaguarnera M, Di Fazio I, Romeo MA, Restuccia S, Laurino A, Trovato BA. Elevation of interleukin 6 levels in patients with chronic hepatitis due to hepatitis C virus. J Gastroenterol 1997;32:211-215.
26. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004;431:461-466.
27. Sriamporn S, Pisani P, Pipitgool V, Suwanrungruang K, Kamsa-ard S, Parkin DM. Prevalence of Opisthorchis viverrini infection and incidence of cholangiocarcinoma in Khon Kaen, Northeast Thailand. Trop Med Int Health 2004;9:588-594.
28. Mairiang E, Elkins DB, Mairiang P, Chaiyakum J, Chamadol N, Loapaiboon V, et al. Relationship between intensity of Opisthorchis viverrini infection and hepatobiliary disease detected by ultrasonography. J Gastroenterol Hepatol 1992;7:17-21.
29. Mairiang E, Haswell-Elkins MR, Mairiang P, Sithithaworn P, Elkins DB. Reversal of biliary tract abnormalities associated with Opisthorchis viverrini infection following praziquantel treatment. Trans R Soc Trop Med Hyg 1993;87:194-197.
30. Landis J, Koch G. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-174.
31. Sripa B, Kaewkes S. Relationship between parasite-specific antibody responses and intensity of Opisthorchis viverrini infection in hamsters. Parasite Immunol 2000;22:139-145.
32. Aida Y, Pabst MJ. Neutrophil responses to lipopolysaccharide. Effect of adherence on triggering and priming of the respiratory burst. J Immunol 1991;146:1271-1276.
33. Dhiensiri T, Eua-Ananta Y, Bunnag D, Harinasuta T, Schelp PF. Roentgenographically controlled healing of gallbladder lesions in opisthorchiasis after praziquantel treatment. Arzneimittelforschung 1984;34:1175-1177.
34. Sripa B, Kaewkes S. Gall bladder and extrahepatic bile duct changes in Opisthorchis viverrini-infected hamsters. Acta Trop 2002;83:29-36.
35. Harinasuta T, Riganti M, Bunnag D. Opisthorchis viverrini infection: pathogenesis and clinical features. Arzneimittelforschung 1984;34:1167-1169.
36. Bhamarapravati N, Thammavit W, Vajrasthira S. Liver changes in hamsters infected with a liver fluke of man, Opisthorchis viverrini. Am J Trop Med Hyg 1978;27:787-794.
37. Tansurat P. Opisthorchiasis. In: Marcial-Rojas RA, ed. Pathology of Protozoal and Helminthic Diseases. Baltimore, MD: Williams and Wilkins; 1971:536-545.
38. Maizels RM, Balic A, Gomez-Escobar N, Nair M, Taylor MD, Allen JE. Helminth parasites - masters of regulation. Immunol Rev 2004;201:89-116.
39. Thuwajit C, Thuwajit P, Kaewkes S, Sripa B, Uchida K, Miwa M, et al. Increased cell proliferation of mouse fibroblast NIH-3T3 in vitro induced by excretory/secretory product(s) from Opisthorchis viverrini. Parasitology 2004;129:455-464.
40. Flavell DJ, Flavell SU. Opisthorchis viverrini: pathogenesis of infection in immunodeprived hamsters. Parasite Immunol 1986;8:455-466.
41. McClain CJ, Song Z, Barve SS, Hill DB, Deaciuc I. Recent advances in alcoholic liver disease. IV. Dysregulated cytokine metabolism in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2004;287:G497-G502.
42. Sheikh MY, Choi J, Qadri I, Friedman JE, Sanyal AJ. Hepatitis C virus infection: molecular pathways to metabolic syndrome. HEPATOLOGY 2008;47:2127-2133.
43. Ghazizadeh M, Tosa M, Shimizu H, Hyakusoku H, Kawanami O. Functional implications of the IL-6 signaling pathway in keloid pathogenesis. J Invest Dermatol 2007;127:98-105.
44. Jittimanee J, Sermswan RW, Puapairoj A, Maleewong W, Wongratanacheewin S. Cytokine expression in hamsters experimentally infected with Opisthorchis viverrini. Parasite Immunol 2007;29:159-167.
45. Prakobwong S, Pinlaor S, Yongvanit P, Sithithaworn P, Pairojkul C, Hiraku Y. Time profiles of the expression of metalloproteinases, tissue inhibitors of metalloproteases, cytokines and collagens in hamsters infected with Opisthorchis viverrini with special reference to peribiliary fibrosis and liver injury. Int J Parasitol 2009;39:825-835.
46. Malhi H, Gores GJ. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol 2006;45:856-867.
47. Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. HEPATOLOGY 2008;12:131-150.